Westin

Where it stands

Deal announced · next: the shareholder vote, awaiting filing

A deal has been announced. Before anyone can redeem, a merger proxy has to be filed — an S-4 or F-4 registration statement, or a preliminary proxy — the SEC has to clear it, and a meeting date has to be set. That meeting is where you redeem. No such date is on file with us, so there is none to show.

Merging with

First Choice Healthcare Solutions, Inc (United States)

Industry

Healthcare — Functional health, longevity and regenerative medicine clinics

Deal value

$650M

announced 23 July 2026

Price vs cash floor

$10.18 vs $10.00

$0.18 above the last filed cash held for you; 14.3% below cash against our estimated ~$11.87

Cash left in trust

$58.4M

IPO

5 November 2025

$58M raised · 100.0% of each $10 unit into trust

Headquarters

SUITE 1165-L 3 COLEMAN STREET #03-24, SINGAPORE, 179804

registered in the Cayman Islands

Lead underwriter

A.G.P./Alliance Global Partners

Key officers

Majawit Stanney Patrick (CFO) · Lim Richard Keng Chong (Director) · Abdul Kadir Nakoorsha Bin (Director)

Listed securities

WSTN common · WSTNU unit $10.28 · WSTNR right $0.17 · WSTN common $10.18

1. No dated redemption election is on file for this name. That is an absence in the record, not proof that the right has gone — but it does mean this page cannot tell you a day to act by.
2. Cash held in trust is $10.00 per share as last filed. That is the figure a redemption pays out at, plus whatever interest the trust earns between the filing and the window.
3. The charter runs to 5 May 2027. If no deal closes by then the trust is returned to holders, which is a floor of a different kind — it pays out, but you do not choose when.

1. 5 November 2025IPOpassed

   $58M raised into trust

2. 23 July 2026Deal announcedpassed

   Combination with First Choice Healthcare

3. 31 March 2027Outside date0001213900-26-082408
4. 5 May 2027Outside date0001213900-26-057804

• First Choice Healthcare$650M · announced 23 July 2026
  announcedHealthcareWeb research

  First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) is a Melbourne, Florida–based healthcare company founded in 2007 that is executing a dramatic strategic pivot away from its legacy orthopedic and physical therapy operations toward building a national chain of functional health, longevity, and regenerative medicine clinics. The company's mission is to deliver clinician-led, whole-person care that integrates primary care, advanced diagnostics, regenerative therapies, medical weight loss, hormone optimization, and compounding pharmacy services. Under CEO Lance Friedman, First Choice is targeting the rapidly expanding wellness and longevity market, which the Global Wellness Institute values at $2.1 trillion in the United States alone and $6.8 trillion globally, forecasting growth to nearly $9.8 trillion by 2029. The company's business model emphasizes cash-pay services to reduce insurance dependency, membership programs for predictable recurring revenue, and compounding pharmacies to support personalized medication offerings for hormone therapy, weight management, and other conditions.

  The company's financial profile reflects the challenges of its ongoing transformation. First Choice reported a net loss of approximately $7.1 million for 2025, with an accumulated deficit of roughly $74.7 million and total indebtedness of about $27.2 million. The company emerged from Chapter 11 bankruptcy in 2022, and its auditors have explicitly flagged substantial doubt about its ability to continue as a going concern without additional capital and successful acquisitions. PitchBook data shows a trailing twelve-month revenue of just $3,320 and a market capitalization of approximately $274,000 as of August 2026, with only eight employees. To accelerate its growth strategy, First Choice has signed definitive agreements to acquire the Pointe Med Entities, including Pointe Medical Services, Live Well Drugstore, Pointe Med Pharmacy, and The Good Clinic, which together would add functional medicine clinics, compounding and community pharmacy operations, and a tech-forward primary care concept to its platform.

  On July 22, 2026, First Choice announced a definitive business combination agreement with Westin Acquisition Corp. (Nasdaq: WSTN), a Cayman Islands–domiciled special purpose acquisition company led by Chairman and CEO Kok Peng Na. The transaction implies a pre-money equity value of approximately $650 million for First Choice, with consideration paid in PubCo common stock based on an equity-value-to-redemption-price formula. The deal includes a $10 million PIPE investment in PubCo preferred stock with an aggregate stated value of $12.5 million. Prior to closing, Westin will domesticate from the Cayman Islands to Nevada and rebrand as Wellgevity 360, Inc., with First Choice surviving as a wholly owned subsidiary. The combined company is expected to trade on Nasdaq, with a post-closing board of five directors, a majority independent. The transaction is targeted to close in the fourth quarter of 2026, subject to SEC effectiveness of a Form S-4 registration statement, Nasdaq listing approval, shareholder consents, and substantially simultaneous completion of the Pointe Med acquisitions, with an outside closing date of March 31, 2027.

  First Choice is pursuing the SPAC route to go public because it provides immediate access to public market capital, strategic flexibility, and the resources needed to scale its national clinic footprint, invest in cutting-edge health technologies, and integrate the planned Pointe Med acquisitions. The company's leadership views the merger as a transformative milestone that will enable rapid operational scaling and expansion of services to a broader patient base seeking longevity and preventive care. The SPAC structure also allows First Choice to execute its rebrand to Wellgevity 360, positioning the combined entity as a next-generation healthcare and wellness platform focused on longevity, preventative care, and pers

  Deal structureSEC-primary — BCA 8-K / S-4 / DEFM14A

  Headline$650MvsEffective$738M+13% dilution

  Effective equity counts every claim on the post-close company at $10.00 — rollover, public shares, the founder promote and the PIPE. The headline counts only the target.

  PIPE

  ≈ $10M · unsourced

  Sponsor promote

  26%

  Exchange ratio

  Floating: Aggregate Merger Consideration = Equity Value divided by the trust Redemption Price, allocated per the Closing Consideration Spreadsheet. On Domestication each Parent Class A Ordinary Share converts into one share of PubCo Common Stock and each Parent Right becomes a right to receive 1/6 of one share.more ▾less ▴

  PIPE structure:

  preferred at a 20% discount to stated value: up to $12,500,000 aggregate stated value of PubCo Preferred Stock for an aggregate purchase price of up to $10,000,000. CONTEMPLATED ONLY — no subscriptionmore ▾less ▴

  PIPE terms — instrument, coupon, conversion price and any reset floor — are not sourced for this deal. The size above is itself unsourced — a stored figure no filing we hold states — so neither the size nor the terms should be read as cited.

  Outside date: 31 March 2027 — the contractual long-stop for closing. It is not a redemption deadline and confers no right to cash.

  stated in:0001213900-26-082408 0001213900-25-107058 0001213900-26-057804

  What it is being valued atSEC-primary — the filed capitalisation table

  What the filings actually value

  They are not the same fact, and only the last one is what a valuation multiple may be struck on.

  Pre-money equity value of the target$650M

  What First Choice Healthcare on its own is valued at, before a dollar of the SPAC's trust or the PIPE reaches it. This is the price agreed for the business itself.

  =Pro-forma enterprise value$650M

  The combined company net of that cash — what the buyers are paying for the BUSINESS. Every multiple below is struck on this figure and on nothing else.

  What that price is, per dollar of sales

  Enterprise value ÷ EBITDA — not shown

  No EBITDA figure for First Choice Healthcare appears in any filing we hold, so no EV/EBITDA multiple is shown. We have not inferred one from a margin assumption — a multiple built on an assumed margin measures the assumption, not the company.

  All figures above are stated in EX-99 press release0001213900-26-082408

  EX-99 press release, 0001213900-26-082408: preMoneyEquityM "approximately $650 million" — the sponsor rounding its own figure; proFormaEnterpriseValueM "approximately $650 million" — the sponsor rounding its own figure. A press release is a party's own claim, not a filed table: any stated capitalisation table supersedes it.

• 8-K29 July 20260001213900-26-082408

  This is the definitive deal announcement for Westin, setting the terms for redemption: trust per share is $10.00, deadline extended to 2027, and a $650M valuation. The sponsor change may be relevant for assessing sponsor alignment and insider support. The target operates in the growing wellness and longevity healthcare market. No PIPE agreements signed yet, adding execution risk.

• 42529 July 20260001213900-26-082414

  This filing provides the full terms of the proposed business combination, including the trust value, redemption mechanics (public shareholders can redeem at the Redemption Price per the trust agreement), extension provisions, and sponsor conduct (including a change of control of the sponsor entity). Investors can now evaluate deal economics, the PIPE backstop (uncommitted as of filing), and governance. The sponsor support agreement reduces the risk of large redemptions by locking in insider votes and no-redemption commitments. The deadline gives a clear timeframe for the proxy vote and closing, and the automatic extension provides a contingency for SEC review. The sponsor change is a notable event that may affect investor confidence or regulatory scrutiny.

• SCHEDULE 13D/A28 July 20260001213900-26-082465

  A total transfer of the holding company fundamentally alters the sponsor and control structure before the documented May 5, 2027 deadline, which directly impacts execution risk and shareholder redemption calculus. The document contains no substantiated claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel; those categories are entirely absent. Because the exhibit omits any reference to the trust per-share balance, no assumption that trusts are fixed at $10.00 can be drawn from this filing, and I note explicitly that trusts are not always $10.00. The substantive takeaway rests on the representational language and the absolute nature of the block transfer, which signals a pivot in corporate control without yet disclosing integration steps, financing arrangements, or target business metrics. Materiality is high given the control shift, though near-term transparency remains limited until successor filings address the merger timeline and capital deployment.

• 10-Q15 May 20260001213900-26-057804

  The disclosure control deficiency flags a potential risk that the sponsor has not been timely disclosing all agreements (e.g., letter-of-intent or earnout terms) that could affect redemption decisions. The negative working capital and going-concern disclosure underscore tight liquidity before the May 5, 2027 deadline. Trust value of $58.4M exceeds the $10.00 trust floor ($57.5M), providing a small buffer for redemption.

• 10-Q13 February 20260001213900-26-016422

  The filing provides the first snapshot of the SPAC's post-IPO financial position and confirms it remains early in its lifecycle with no target selected. The disclosed going concern uncertainty and material weakness in internal controls are important operational red flags. The trust account holds $57.89 million, with $10.00 per public share initially anticipated for redemption, and the company has a business combination deadline of May 5, 2027.

• 8-K23 December 20250001213900-25-124959

  Investors tracking redemption mechanics should note this document contains no amended proxy statements, no notice of a special meeting, and no adjustments to the contractual deadline or trust distribution waterfalls; consequently, the procedures for invoking cash redemptions remain unchanged. Per the press release, Westin Acquisition Corp continues to operate as a blank check company structured to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination, with a stated approach that will not be limited to a particular industry or geographic region. Administrative unit separation typically precedes definitive merger agreements and allows secondary markets to price the equity and rights components independently, which shapes shareholder evaluation once management presents a specific business combination valuation and redemption framework. The filing was executed on behalf of the registrant by Chief Executive Officer and Chairman Kok Peng Na, and designates Chief Financial Officer Stanney P. Majawit as the investor contact. Because the submission adjusts trading conventions rather than altering capital commitments, liquidation priority, or fiduciary obligations, it functions as a structural liquidity update rather than a substantive deal milestone.

• 42529 July 20260001213900-26-082414

  What changed: Current Report on Form 8-K filed as a Rule 425 communication, announcing the definitive Business Combination Agreement between Westin Acquisition Corp. (SPAC) and First Choice Healthcare Solutions, Inc., including full text of the BCA, Parent Support Agreement, Company Support Agreement, form of Lock-Up Agreement, form of Registration Rights Agreement, Share Transfer Agreement, and press release. Initial definitive deal announcement: (1) SPAC to domesticate from Cayman to Nevada and rename Wellgevity 360, Inc.; (2) target valued at up to ~$650 million equity value; (3) PIPE investment of up to $10,000,000 (stated value $12,500,000) contemplated but not yet committed; (4) trust account had at least $58,360,098 as of March 31, 2026; (5) closing deadline March 31, 2027, auto-extending to April 30, 2027 if S-4 not effective by Feb. 28, 2027; (6) sponsor change: Westin Ventures Holdings Ltd. transferred all Sponsor shares to EU Asia Holidays Pte. Ltd. for $1 plus other consideration, with ultimate controlling person changing from Kok Peng Na to Hanjie Ong; (7) Sponsor and certain other Parent shareholders entered into Parent Support Agreement agreeing not to redeem or transfer shares and to vote in favor; (8) target concurrently acquiring Pointe Med Entities substantially at closing; (9) post-closing board to consist of 5 directors (1 by Sponsor, 3 by Company, CEO); (10) lock-up period of 6 months for Sponsor and certain stockholders with potential early release at $18.00 for 30 days. Why it matters: This filing provides the full terms of the proposed business combination, including the trust value, redemption mechanics (public shareholders can redeem at the Redemption Price per the trust agreement), extension provisions, and sponsor conduct (including a change of control of the sponsor entity). Investors can now evaluate deal economics, the PIPE backstop (uncommitted as of filing), and governance. The sponsor support agreement reduces the risk of large redemptions by locking in insider votes and no-redemption commitments. The deadline gives a clear timeframe for the proxy vote and closing, and the automatic extension provides a contingency for SEC review. The sponsor change is a notable event that may affect investor confidence or regulatory scrutiny.

• 8-K29 July 20260001213900-26-082408

  What changed: 8-K filed July 29, 2026, announcing a definitive Business Combination Agreement between Westin Acquisition Corp. (SPAC) and First Choice Healthcare Solutions, Inc., along with a sponsor share transfer that changed control of the sponsor. Westin entered into a Business Combination Agreement with First Choice Healthcare Solutions, valued at up to $650 million. Concurrently, the sponsor (Westin Investment Co. Ltd.) was sold by Westin Ventures Holdings Ltd. to EU Asia Holidays Pte. Ltd. for $1.00, resulting in Mr. Hanjie Ong becoming the ultimate controlling person of the sponsor. The sponsor continues to hold 2,012,500 Class B shares and 235,000 private placement units, representing ~27.9% of outstanding ordinary shares. The SPAC will domesticate to Nevada and rename to Wellgevity 360, Inc. A PIPE of up to $10 million (stated value $12.5M) is contemplated but not yet executed. The target also has binding agreements to acquire Pointe Med Entities concurrently with closing. Closing deadline is March 31, 2027 (auto-extend to April 30, 2027 if SEC effectiveness delayed). Why it matters: This is the definitive deal announcement for Westin, setting the terms for redemption: trust per share is $10.00, deadline extended to 2027, and a $650M valuation. The sponsor change may be relevant for assessing sponsor alignment and insider support. The target operates in the growing wellness and longevity healthcare market. No PIPE agreements signed yet, adding execution risk.

• SCHEDULE 13D/A28 July 20260001213900-26-082465

  What changed: This filing IS a Schedule 13D/A beneficial ownership report appended with Exhibit 4: a Share Transfer Agreement dated July 25, 2026. Concerning SPAC mechanics, the filing records no adjustments to the redemption calendar, trust account valuations, extension votes, or the announced merger status. The attached agreement stipulates that Westin Ventures Holdings Ltd. conveys 100 percent of its outstanding equity to EU Asia Holidays Pte. Ltd. for US$1.00 and other good and valuable consideration. Completion is scheduled for the Effective Date of July 25, 2026, requiring delivery of share certificates and updating the register of members. Signatory Mr. Kok Peng Na executes for the Transferor, while signatory Mr. Hanjie Ong executes for the Transferee. The Transferor represents that it is the sole legal and beneficial owner, that the shares are fully paid, and that they carry no liens, charges, pledges, encumbrances, or third-party rights. Governing law is listed as the jurisdiction of incorporation (British Virgin Islands), and the Transferee’s Singapore registration number is cited as 201317245C. Why it matters: A total transfer of the holding company fundamentally alters the sponsor and control structure before the documented May 5, 2027 deadline, which directly impacts execution risk and shareholder redemption calculus. The document contains no substantiated claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel; those categories are entirely absent. Because the exhibit omits any reference to the trust per-share balance, no assumption that trusts are fixed at $10.00 can be drawn from this filing, and I note explicitly that trusts are not always $10.00. The substantive takeaway rests on the representational language and the absolute nature of the block transfer, which signals a pivot in corporate control without yet disclosing integration steps, financing arrangements, or target business metrics. Materiality is high given the control shift, though near-term transparency remains limited until successor filings address the merger timeline and capital deployment.

• SCHEDULE 13G14 July 20260001140361-26-028387

  What changed: A Schedule 13G beneficial ownership report identifying Wolverine Asset Management, LLC, Wolverine Holdings, LLC, Christopher L. Gust, and Robert R. Bellick as the reporting holders for WSTN. The filing registers these four entities and individuals as crossing regulatory disclosure thresholds for WSTN shares. The submitted text contains no percentages, acquisition dates, share quantities, purchase prices, or dollar values. Accordingly, the filing discloses nothing regarding redemption deadlines, trust account balances, extension mechanisms, business combination milestones, or sponsor conduct. Why it matters: Under Securities and Exchange Commission rules, a Schedule 13G indicates that the named parties have attained beneficial ownership sufficient to warrant public reporting without a controlling purpose. Because the excerpt omits the exact stake acquired, the transaction date, and any voting or disposition agreements, the report provides no verifiable evidence of fresh capital entering the SPAC, supplemental private placement commitments, or shifts in merger pathway execution. Investors monitoring liquidity windows, trust preservation, or sponsor accountability will find no actionable mechanics in this snippet; the filing merely logs these holders’ statutory disclosures pending review of the complete exhibit for percentage figures, execution dates, and any attached statements regarding plan or purpose.

• 10-Q15 May 20260001213900-26-057804

  What changed: Quarterly report on Form 10-Q for the period ended March 31, 2026 — a standard periodic filing for a blank-check SPAC that completed its IPO in November 2025. First periodic report since the IPO closing. The trust account holds $58,360,098 against $57,500,000 of gross proceeds; trust-per-share ratio stands at roughly $10.15 (including earnings). Working capital outside trust is negative $149,751. The company reports a material weakness in disclosure controls and procedures related to identifying and disclosing commitment and contingencies agreements. No business combination target has been selected, and no substantive discussions have been initiated with any target. Why it matters: The disclosure control deficiency flags a potential risk that the sponsor has not been timely disclosing all agreements (e.g., letter-of-intent or earnout terms) that could affect redemption decisions. The negative working capital and going-concern disclosure underscore tight liquidity before the May 5, 2027 deadline. Trust value of $58.4M exceeds the $10.00 trust floor ($57.5M), providing a small buffer for redemption.

  trust account, combination deadline, going-concern doubt +2nothing moved · 5 with no prior record of ours

  Trust account

  $57.5M · unchanged

  The clause “288,371 ) Cash Flows from Investing Activity Purchase of marketable securities held in Trust Account ( 57,500,000 ) Net cash used in investing activity ( 57,500,000 ) Cash Flows from Financing Activities Proceeds from sale of public”…

  Combination deadline

  2027-05-05 · unchanged

  The clause …“of an initial Business Combination. In addition, the Company currently has until May 5, 2027 (unless the Company extends such period by amending its Amended and Restated Memorandum and Articles of Association) to consummate the”…

  Going-concern doubt

  stated · unchanged

  The clause “014-15, Disclosures of Uncertainties about an Entity s Ability to Continue as a Going Concern, management has determined that the mandatory liquidation, should a business combination not occur, and potential subsequent dissolution, raises”…

  Sponsor loans outstanding

  $449K · unchanged

  The clause …“promissory note loans provided by the Sponsor. As of March 31, 2026, $449,377 was outstanding under the promissory note. 18 The Company has incurred and expects to continue to incur significant costs in pursuit of the”…

  Redeemable shares

  5.00M · unchanged

  The clause “475 Class A ordinary shares, $ 0.0001 par value, 450,000,000 shares authorized, 5,000,000 shares subject to possible redemption as of March 31, 2026 51,743,085 - Commitment and contingencies (Note 6) Shareholders Equity Class A ordinary”…

  Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.

Market data as of 2026-08-19 (22 days old). A forward multiple is a market opinion on one day, not a filed figure.

Selected from a listed universe by sector and by business description — not from the SPAC's stated mandate.

Reality check: Binary: RACC +140% on announcement vs Instinct Bio -96% in two weeks (same month). (research 2026-08-10)